Affiliated Researchers

Clinical Evidence Synthesis

To further support ICER’s work in evidence synthesis and interpretation, ICER partners with several external clinical epidemiologists for some of our reviews. These partners include:

Steven Atlas, MD

Associate Professor of Medicine, Harvard Medical School
Director of Practice-Based Research and Quality Improvement
Division of General Internal Medicine, Massachusetts General Hospital

Jeffrey A. Tice, MD
Department of Medicine
Division of General Internal Medicine
University of California San Francisco

Health Economics Council

To ensure that all reports incorporate the most up-to-date methods and best practices in health economics, ICER collaborates with an academic council of experts, leveraging their expertise to support ICER’s work in assessing drugs and other interventions. Currently, ICER’s health economics partners include:

The University of Colorado’s Skaggs School of Pharmacy and Pharmaceutical Sciences’ Center for Pharmaceutical Outcomes Research (CePOR)

The major goal of CePOR is to promote training and interdisciplinary research collaborations in the areas of pharmacoeconomics, health services and systems research, drug policy, health benefits design, pharmacoepidemiology, and drug safety.

Read more about this collaboration here.

The University of Illinois at Chicago College of Pharmacy’s Center for Pharmacoepidemiology and Pharmacoeconomic Research (CPR)

The goal of the Center is to advance understanding of the impact of pharmacy and health care services, products, and policy by conducting research in pharmacoeconomics, pharmacoepidemiology, and patient-centered outcomes; translating and disseminating research; and educating, training, and mentoring researchers.

Read more about this collaboration here. 

The University of Washington School of Pharmacy’s Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

The CHOICE Institute conducts research and provides graduate and external training in health outcomes and policy research on health care technologies, with a focus on drugs, diagnostics, and devices. The overall goal of the program is to generate evidence that improves health care decisions for patients, clinicians, payers, industry and government organizations. The CHOICE Institute is a nationally and internationally recognized center for pharmaceutical economics, drug safety, and pharmaceutical policy research.

Read more about this collaboration here.